ArticleAnnals of translational medicine2025
Breaking new ground in ductal carcinoma in situ management: the promise of intratumoral messenger ribonucleic acid-2752 and pembrolizumab.
Ciara C O'Sullivan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.